Log In
BCIQ
Print this Print this
 

CHP-NY-ESO-1 (IMF-001)

  Manage Alerts
Collapse Summary General Information
Company ImmunoFrontier Inc.
DescriptionCancer vaccine consisting of a recombinant protein of cancer antigen NY-ESO-1 and a polysaccharide-based delivery system (cholesteryl pullulan)
Molecular Target Cancer/testis antigen 1B (NY-ESO-1) (CTAG1B)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today